Pfizer Inc. has expanded on the long lead it had with Xeljanz (tofacitinib) over competing Janus kinase (JAK) inhibitors by engineering more selective next-generation drugs in this class, including abrocitinib, for which the company presented the first detailed Phase III atopic dermatitis (AD) data on 12 October in a late-breakers session at the European Academy of Dermatology and Venereology (EADV) meeting in Madrid.
[Sidebar#SC125232]







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)